|Bid||51.00 x 1100|
|Ask||64.00 x 1200|
|Day's Range||58.37 - 61.31|
|52 Week Range||19.31 - 99.50|
|Beta (3Y Monthly)||2.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||131.57|
IRVING, Texas, Oct. 16, 2018 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s.
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Statistically Significant Improvement in Kidney Function Observed in Both Diseases After 12 Weeks of Treatment Conference Call with Management Scheduled for Today at 8:00 am ET.
Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellularRead More...
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that it has received a $30 million milestone payment from its licensee, Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), following the initiation of AYAME, a Phase 3 clinical trial to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan. In December 2009, Reata granted Kyowa Hakko Kirin the exclusive license to develop and commercialize bardoxolone in renal disease and certain other indications in Japan, China, Taiwan, South Korea, and Southeast Asia.
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -40.54% and -16.89%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
IRVING, Texas, Aug. 08, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today provided an update on the Company's product development programs and announced financial results ...
IRVING, Texas, Aug. 06, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and live webcast on Wednesday, August ...
These stocks jumped much higher over the last few days. But should investors jump on the bandwagon?
Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3,450,000 shares of its Class A common stock, which included 450,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $72.00 per share. The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $248.4 million. Reata intends to use the net proceeds from the offering for working capital and general corporate purposes, which include, but are not limited to, advancing the development of bardoxolone methyl and omaveloxolone through clinical trials, preparing to file one or more New Drug Applications, and planning for commercialization of its potential products.
NEW YORK, July 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Reata ...
CORAL GABLES, FL / ACCESSWIRE / July 24, 2018 / The Nasdaq Biotechnology Index (IBB) just made a new 52-week high today and most likely an all-time high may not be out of the question either. As most of the market shutters about the trade wars, biotech stocks are more insulated from the biggest concern about tariffs compared to most industries. Biotech companies like GT Biopharma, Inc. (GTBP), Reata Pharmaceuticals (NASDAQ: RETA) and Biogen (NASDAQ: BIIB) have all released news within the last 10 days that has sparked much more interest in the market for these stocks.
NEW YORK, NY / ACCESSWIRE / July 24, 2018 / Both Reata Pharmaceuticals and LifePoint were trading significantly higher on strong trading volume after Wall Street learned about positive developments from ...
Today, Reata Pharmaceuticals is trading at a stock price of $75.00, which represents a ~61.67% hike from yesterday’s close of $46.4. On July 20, Reata Pharmaceuticals closed at $46.4, which represents ~140% growth from its 52-week low of $19.31 on March 29. Also today, Reata Pharmaceuticals hit a 52-week high of $76.25.